Search

Your search keyword '"Trepel, Martin"' showing total 265 results
Start Over Author "Trepel, Martin" Language english
265 results on '"Trepel, Martin"'

1. Experience of rescue therapy with [177Lu]Lu-rhPSMA-10.1 in patients with primary or acquired resistance to [177Lu]Lu-PSMA-I&T

Author

Gäble, Alexander, Dierks, Alexander, Rinscheid, Andreas, Patt, Marianne, Wienand, Georgine, Pfob, Christian H., Kircher, Malte, Fukushima, Kazuhito, Nikolić, Ana Antić, Enke, Johanna S., Janzen, Tilman, Steinestel, Julie, Kempter, Hildegard, Trepel, Martin, Weckermann, Dorothea, Lapa, Constantin, and Bundschuh, Ralph A.

Published
2024
Full Text
View/download PDF

6. Concept and feasibility of the Augsburg Longitudinal Plasma Study (ALPS) – a prospective trial for comprehensive liquid biopsy-based longitudinal monitoring of solid cancer patients

Author

Sommer Sebastian, Schmutz Maximilian, Hildebrand Kathrin, Schiwitza Annett, Benedikt Selinah, Eberle Maria, Mögele Tatiana, Sultan Aziz, Reichl Lena, Campillo Maria, Uhrmacher Luise, Nikolic Ana Antic, Bundschuh Ralph, Lapa Constantin, Kuhlen Michaela, Dintner Sebastian, Langer Angela, Märkl Bruno, Wendler Thomas, Tehlan Kartikay, Kröncke Thomas, Wahle Maria, Mann Matthias, Casadei Nicolas, Pogoda Michaela, Hummler Simone, Sax Irmengard, Schlesner Matthias, Kubuschok Boris, Trepel Martin, and Claus Rainer

Subjects
liquid biopsy, ctdna, longitudinal profiling, clonal evolution, spatial heterogeneity, translational research, Medical technology, R855-855.5
Abstract

Liquid biopsy (LBx) provides diagnostic, prognostic and predictive insights for malignant diseases and offers promising applications regarding tumor burden, tumor heterogeneity and clonal evolution.

Published
2024
Full Text
View/download PDF

7. Unraveling the role of local ablative therapies for patients with metastatic soft tissue sarcoma – A retrospective multicenter study of the Bavarian university hospitals

Author

Burkhard-Meier, Anton, Grube, Matthias, Jurinovic, Vindi, Agaimy, Abbas, Albertsmeier, Markus, Berclaz, Luc M., Di Gioia, Dorit, Dürr, Hans Roland, von Eisenhart-Rothe, Rüdiger, Eze, Chukwuka, Fechner, Katja, Fey, Emma, Güler, Sinan E., Hecker, Judith S., Hendricks, Anne, Keil, Felix, Klein, Alexander, Knebel, Carolin, Kovács, Julia R., Kunz, Wolfgang G., Lenze, Ulrich, Lörsch, Alisa M., Lutz, Mathias, Meidenbauer, Norbert, Mogler, Carolin, Schmidt-Hegemann, Nina-Sophie, Semrau, Sabine, Sienel, Wulf, Trepel, Martin, Waldschmidt, Johannes, Wiegering, Armin, and Lindner, Lars H.

Published
2024
Full Text
View/download PDF

8. The WERA cancer center matrix: Strategic management of patient access to precision oncology in a large and mostly rural area of Germany

Author

Krebs, Markus, Haller, Florian, Spörl, Silvia, Gerhard-Hartmann, Elena, Utpatel, Kirsten, Maurus, Katja, Kunzmann, Volker, Chatterjee, Manik, Venkataramani, Vivek, Maatouk, Imad, Bittrich, Max, Einwag, Tatjana, Meidenbauer, Norbert, Tögel, Lars, Hirsch, Daniela, Dietmaier, Wolfgang, Keil, Felix, Scheiter, Alexander, Immel, Alexander, Heudobler, Daniel, Einhell, Sabine, Kaiser, Ulrich, Sedlmeier, Anja M., Maurer, Julia, Schenkirsch, Gerhard, Jordan, Frank, Schmutz, Maximilian, Dintner, Sebastian, Rosenwald, Andreas, Hartmann, Arndt, Evert, Matthias, Märkl, Bruno, Bargou, Ralf, Mackensen, Andreas, Beckmann, Matthias W., Pukrop, Tobias, Herr, Wolfgang, Einsele, Hermann, Trepel, Martin, Goebeler, Maria-Elisabeth, Claus, Rainer, Kerscher, Alexander, and Lüke, Florian

Published
2024
Full Text
View/download PDF

10. Circulating Tumor DNA for Prediction of Complete Pathological Response to Neoadjuvant Radiochemotherapy in Locally Advanced Rectal Cancer (NEORECT Trial).

Author

Mögele, Tatiana, Höck, Michael, Sommer, Florian, Friedrich, Lena, Sommer, Sebastian, Schmutz, Maximilian, Altenburger, Amadeus, Messmann, Helmut, Anthuber, Matthias, Kröncke, Thomas, Stüben, Georg, Trepel, Martin, Märkl, Bruno, Dintner, Sebastian, and Claus, Rainer

Abstract

Simple Summary: The NEORECT trial explored the use of circulating tumor DNA (ctDNA) dynamics as a biomarker to monitor treatment response in rectal cancer patients undergoing nCRT. Although ctDNA patterns showed some correlation with treatment outcomes, specificity was low, indicating limitations in using ctDNA alone to predict pathologic remission. The findings highlight the potential and challenges of ctDNA-based monitoring, suggesting that broader genetic analysis and larger studies are needed to enhance precision in non-surgical management approaches. Background/Objectives: Locally advanced rectal cancer is treated with neoadjuvant chemoradiotherapy (nCRT) followed by total mesorectal excision (TME). As this approach achieves complete pathologic remissions (pCR) in approximately 30% of patients, it raises the question of whether surgery is always necessary. Non-surgical strategies, such as "watch and wait" (W&W), have shown similarly promising outcomes. However, there is an unmet need for reliable biomarkers predicting pCR. Analysis of circulating tumor DNA (ctDNA) has shown potential for monitoring treatment response and detecting minimal residual disease. We hypothesized that monitoring ctDNA changes during nCRT might facilitate the identification of individuals who achieve pCR. Methods: In the prospective single-center NEORECT trial, the plasma of forty rectal cancer patients was collected before, during, and after nCRT and before TME. Informative somatic mutations were identified in tissue biopsies by NGS and subsequently used for ctDNA quantification by dPCR. Results: The results identified three distinct ctDNA patterns: increase, decrease, and absence. Remarkably, undetectable DNA was observed in good responders, while a tenfold ctDNA increase was associated with the emergence of new metastases. Despite these insights, ctDNA alone demonstrated low specificity, with no significant correlation to pCR or long-term prognosis. A multimodal approach incorporating routinely available clinical parameters remains inadequate for accurately predicting pCR prior to TME. Conclusions: In conclusion, the NEORECT trial establishes the feasibility of ctDNA-based personalized monitoring for rectal cancer patients undergoing nCRT. However, the utility of ctDNA in enhancing pCR prediction for a W&W strategy warrants further investigation. Larger studies integrating multi-gene analyses and expanded clinical datasets are essential in the future. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

12. Non-productive angiogenesis disassembles Aß plaque-associated blood vessels

Author

Alvarez-Vergara, Maria I., Rosales-Nieves, Alicia E., March-Diaz, Rosana, Rodriguez-Perinan, Guiomar, Lara-Ureña, Nieves, Ortega-de San Luis, Clara, Sanchez-Garcia, Manuel A., Martin-Bornez, Miguel, Gómez-Gálvez, Pedro, Vicente-Munuera, Pablo, Fernandez-Gomez, Beatriz, Marchena, Miguel A., Bullones-Bolanos, Andrea S., Davila, Jose C., Gonzalez-Martinez, Rocio, Trillo-Contreras, Jose L., Sanchez-Hidalgo, Ana C., del Toro, Raquel, Scholl, Francisco G., Herrera, Eloisa, Trepel, Martin, Körbelin, Jakob, Escudero, Luis M., Villadiego, Javier, Echevarria, Miriam, de Castro, Fernando, Gutierrez, Antonia, Rabano, Alberto, Vitorica, Javier, and Pascual, Alberto

Published
2021
Full Text
View/download PDF

16. Pro-Fibrotic Effects of CCL18 on Human Lung Fibroblasts Are Mediated via CCR6.

Author

Höhne, Kerstin, Wagenknecht, Annett, Maier, Corinna, Engelhard, Peggy, Goldmann, Torsten, Schließmann, Stephan J., Plönes, Till, Trepel, Martin, Eibel, Hermann, Müller-Quernheim, Joachim, and Zissel, Gernot

Subjects
LUNGS, CHEMOKINE receptors, CHEMOKINES, IDIOPATHIC pulmonary fibrosis, FIBROBLASTS, LUNG diseases
Abstract

Background: Idiopathic pulmonary fibrosis (IPF) is a fatal lung disease of unknown origin, with a median patient survival time of ~3 years after diagnosis without anti-fibrotic therapy. It is characterized by progressive fibrosis indicated by increased collagen deposition and high numbers of fibroblasts in the lung. It has been demonstrated that CCL18 induces collagen and αSMA synthesis in fibroblasts. We aimed to identify the CCL18 receptor responsible for its pro-fibrotic activities. Methods: We used a random phage display library to screen for potential CCL18-binding peptides, demonstrated its expression in human lungs and fibroblast lines by PCR and immunostaining and verified its function in cell lines. Results: We identified CCR6 (CD196) as a CCL18 receptor and found its expression in fibrotic lung tissue and lung fibroblast lines derived from fibrotic lungs, but it was almost absent in control lines and tissue. CCL18 induced receptor internalization in a CCR6-overexpressing cell line. CCR6 blockade in primary human lung fibroblasts reduced CCL18-induced FGF2 release as well as collagen-1 and αSMA expression. Knockdown of CCR6 in a mouse fibroblast cell line abolished the induction of collagen and α-smooth muscle actin expression. Conclusion: Our data indicate that CCL18 triggers pro-fibrotic processes via CCR6, highlighting its role in fibrogenesis. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

20. Recording of the regional origin areas of patients from the molecular tumor board to identify the 'white spots' in the service area - a joint initiative of the Bavarian CCC WERA alliance [Abstract]

Author

Lüke, F., Haller, F., Utpatel, K., Krebs, M., Meidenbauer, N., Scheiter, A., Spörl, S., Heudobler, D., Keil, F., Schubart, C., Tögel, L., Einhell, S., Dietmaier, W., Huss, Ralf, Dintner, Sebastian, Sommer, Sebastian, Jordan, Frank, Göbeler, M. E., Metz, M., Haake, D., Scheytt, M., Gerhard-Hartmann, E., Maurus, K., Brändlein, S., Rosenwald, A., Hartmann, A., Märkl, Bruno, Einsele, H., Mackensen, A., Herr, W., Kunzmann, V., Bargou, R., Beckmann, M., Pukrop, T., Trepel, Martin, Evert, M., Claus, Rainer, and Kerscher, A.

Subjects
ddc:610
Published
2022

26. Vascular ligand-receptor mapping by direct combinatorial selection in cancer patients

Author

Staquicini, Fernanda I., Cardó-Vila, Marina, Kolonin, Mikhail G., Trepel, Martin, Edwards, Julianna K., Nunes, Diana N., Sergeeva, Anna, Efstathiou, Eleni, Sun, Jessica, Almeida, Nalvo F., Tu, Shi-Ming, Botz, Gregory H., Wallace, Michael J., O'Connell, David J., Krajewski, Stan, Gershenwald, Jeffrey E., Molldrem, Jeffrey J., Flamm, Anne L., Koivunen, Erkki, Pentz, Rebecca D., Dias-Neto, Emmanuel, Setubal, João C., Cahill, Dolores J., Troncoso, Patricia, Do, Kim-Ahn, Logothetis, Christopher J., Sidman, Richard L., Pasqualini, Renata, and Arap, Wadih

Published
2011

30. No association of malignant B‐cell non‐Hodgkin lymphomas with ipsilateral SARS‐CoV‐2 vaccination.

Author

Claaß, Luise Victoria, Mayr, Patrick, Paschold, Lisa, Weber, Thomas, Terziev, Denis, Jehs, Bertram, Brill, Richard, Dober, Johannes, Märkl, Bruno, Wickenhauser, Claudia, Czapiewski, Piotr, Trepel, Martin, Claus, Rainer, and Binder, Mascha

Subjects
COVID-19 vaccines, VACCINATION, DIFFUSE large B-cell lymphomas, LYMPHOMAS, LYMPHADENITIS, SARS-CoV-2, ACADEMIC medical centers
Abstract

Purpose: SARS‐CoV‐2 vaccines cause acute ipsilateral lymph node swelling in an important proportion of vaccines. Thus far, no malignant lymphadenopathies have been reported in temporal context to vaccination in the ipsilateral draining lymph node areas. Experimental design: Prompted by two cases with unilateral axillary lymphomas that occurred ipsilaterally to prior SARS‐CoV‐2 vaccination, we systematically retrieved all B‐cell non‐Hodgkin lymphomas at two German University Medical Centers diagnosed before and after introduction of SARS‐CoV‐2 vaccines in Germany. Available lymphoma tissue (n=19) was subjected to next‐generation immunosequencing of the IGH locus. Malignant clonotypes were mined in the CoVabDab database and published data sets from 342 uninfected individuals, 55 individuals 28 days after anti‐SARS‐CoV‐2 vaccination and 139 individuals with acute COVID‐19 together encompassing over 1 million CDR3 sequences in total. Results: Of 313 newly diagnosed cases in the two centers and observation periods, 27 unilateral manifestations in the defined deltoid draining regions were identified. The majority thereof were diffuse large B‐cell lymphomas (18 of 27 cases). Eleven unilateral cases were diagnosed in the era of SARS‐CoV‐2 vaccination and 16 in the control period before introduction of such vaccines. Of the 11 unilateral lymphomas that occurred during the vaccination period, ten had received a SARS‐CoV‐2 vaccine prior to lymphoma diagnosis. These cases were further evaluated. While left‐sided were more frequent than right‐sided lymphomas (19 vs 8 cases), no statistically significant association of vaccination site and laterality of the lymphoma manifestation was found. The unilateral lymphomas showed a normal range of B‐cell receptors typically found in these lymphoma subtypes with no evidence for anti‐SARS‐CoV‐2 sequences in the malignant clonotype. Conclusions: Together, we found no evidence that the current SARS‐CoV‐2 vaccines could serve as a trigger for lymphomagenesis in the draining lymph node areas of the deltoid region used for vaccination. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

33. Erhebung der Notwendigkeit einer interdisziplinären virtuellen Tumorkonferenz für neuroonkologische Patienten - vorläufige Ergebnisse einer Zuweiserumfrage

Author

Sommer, Björn, Hackanson, Björn, Konietzko, Ina, Kahl, Klaus-Henning, Stüben, Georg, Berlis, Ansgar, Maurer, Christoph, Märkl, Bruno, Schmid, Christoph, Trepel, Martin, and Shiban, Ehab

Subjects
ddc: 610, 610 Medical sciences, Medicine
Abstract

Objective: The ongoing improvements in oncology and the demographic development in western countries have led to an over proportional increase in cancer patients. Cancer care is best facilitated through tumor board (TB) conferences, as these are associated with overall improvement of outcome. Because[for full text, please go to the a.m. URL], 72. Jahrestagung der Deutschen Gesellschaft für Neurochirurgie (DGNC), Joint Meeting mit der Polnischen Gesellschaft für Neurochirurgie

Published
2021

37. Impact of PTPN11 mutations on clinical outcome analyzed in 1529 patients with acute myeloid leukemia

Author

Stasik, Sebastian, Eckardt, Jan-Niklas, Kramer, Michael, Röllig, Christoph, Krämer, Alwin, Scholl, Sebastian, Hochhaus, Andreas, Crysandt, Martina, Brümmendorf, Tim H., Naumann, Ralph, Steffen, Björn, Kunzmann, Volker, Einsele, Hermann, Schaich, Markus, Burchert, Andreas, Neubauer, Andreas, Schäfer-Eckart, Kerstin, Schliemann, Christoph, Krause, Stefan, Herbst, Regina, Hänel, Mathias, Frickhofen, Norbert, Noppeney, Richard, Kaiser, Ulrich, Baldus, Claudia D., Kaufmann, Martin, Rácil, Zdenek, Platzbecker, Uwe, Berdel, Wolfgang E., Mayer, Jiri, Serve, Hubert, Müller-Tidow, Carsten, Ehninger, Gerhard, Bornhäuser, Martin, Schetelig, Johannes, Middeke, Jan M., Thiede, Christian, Schulz-Abelius, Armin, Trepel, Martin, Teichmann, Martina, Kiani, Alexander, Glaß, Bertram, Görner, Martin, Behringer, Dirk, Kullmer, Johannes, Lamberti, Christof, Schmidt-Hieber, Martin, Flaßhove, Michael, MacKensen, Andreas, Hanoun, Maher, Kiehl, Michael, Höffkes, H.-G., Müller, Lutz Peter, Dürk, Heinz Albert, Held, Gerhard, Repp, Roland Peter, Baldus, Claudia, Chemnitz, Jens-Marcus, Klein, Stefan, Wilhelm, Martin, Schubert, Jörg, Meinhardt, Achim, Geer, Thomas, Ritter, Markus, Aulitzky, Walter Erich, and Heinz, Natalia

Subjects
Neuroblastoma RAS viral oncogene homolog, Oncology, musculoskeletal diseases, medicine.medical_specialty, NPM1, congenital, hereditary, and neonatal diseases and abnormalities, Medizin, Protein Tyrosine Phosphatase, Non-Receptor Type 11, Context (language use), 03 medical and health sciences, 0302 clinical medicine, Internal medicine, Phosphoprotein Phosphatases, medicine, Humans, skin and connective tissue diseases, 030304 developmental biology, 0303 health sciences, Myeloid Neoplasia, business.industry, Remission Induction, Hazard ratio, Cytogenetics, Myeloid leukemia, Hematology, Odds ratio, Prognosis, 3. Good health, PTPN11, Leukemia, Myeloid, Acute, 030220 oncology & carcinogenesis, Mutation, business, Nucleophosmin
Abstract

The tyrosine-protein phosphatase nonreceptor type 11 (PTPN11) is an important regulator of RAS signaling and frequently affected by mutations in patients with acute myeloid leukemia (AML). Despite the relevance for leukemogenesis and as a potential therapeutic target, the prognostic role is controversial. To investigate the prognostic impact of PTPN11 mutations, we analyzed 1529 adult AML patients using next-generation sequencing. PTPN11 mutations were detected in 106 of 1529 (6.93%) patients (median VAF: 24%) in dominant (36%) and subclonal (64%) configuration. Patients with PTPN11 mutations were associated with concomitant mutations in NPM1 (63%), DNMT3A (37%), and NRAS (21%) and had a higher rate of European LeukemiaNet (ELN) favorable cytogenetics (57.8% vs 39.1%; P < .001) and higher white blood cell counts (P = .007) compared with PTPN11 wild-type patients. In a multivariable analysis, PTPN11 mutations were independently associated with poor overall survival (hazard ratio [HR]: 1.75; P < .001), relapse-free survival (HR: 1.52; P = .013), and a lower rate of complete remission (odds ratio: 0.46; P = .008). Importantly, the deleterious effect of PTPN11 mutations was confined predominantly to the ELN favorable-risk group and patients with subclonal PTPN11 mutations (HR: 2.28; P < .001) but not found with dominant PTPN11 mutations (HR: 1.07; P = .775), presumably because of significant differences within the rate and spectrum of associated comutations. In conclusion, our data suggest an overall poor prognostic impact of PTPN11 mutations in AML, which is significantly modified by the underlying cytogenetics and the clonal context in which they occur.

Published
2021

44. Breast cancer

Author

Behringer, D., Waller, C. F., and Trepel, Martin

Published
2020

48. Transfusion‐refractory pancytopenia with MDS‐like morphologic alterations of the bone marrow in a 29‐year old man: A mimicry manifestation caused by scurvy.

Author

Mayr, Patrick, Grünewald, Tatiana, Filippini Velazquez, Giuliano, Rank, Andreas, Schmid, Christoph, Harloff, Manuela, Märkl, Bruno, Trepel, Martin, Hirschbühl, Klaus, Pfeiffer, Tim, and Claus, Rainer

Subjects
PANCYTOPENIA, BONE marrow, SCURVY, PROSTATITIS, BLOOD diseases
Abstract

Scurvy is ancient disease caused by low or depleted levels of vitamin C (ascorbic acid, VITC) and described throughout history. With VITC supplementation, the prognosis is excellent and symptoms resolve within a short time, whereas scurvy is usually fatal if untreated.2 Literature describes cases of pancytopeniaand bone marrow abnormalities in scurvy.3-6 MDS (myelodysplastic syndrome)-like bone marrow manifestations haven't been reported, yet. Transfusion-refractory pancytopenia with MDS-like morphologic alterations of the bone marrow in a 29-year old man: A mimicry manifestation caused by scurvy. [Extracted from the article]

Published
2022
Full Text
View/download PDF

49. Steps toward mapping the human vasculature by phage display

Author

Arap, Wadih, Kolonin, Mikhail G., Trepel, Martin, Lahdenranta, Johanna, Cardo-Vila, Marina, Giordano, Ricardo J., Mintz, Paul J., Ardelt, Peter U., Yao, Virginia J., Vidal, Claudia I., Chen, Limor, Flamm, Anne, Valtanen, Heli, Weavind, Lisa M., Hicks, Marshall E., Pollock, Raphael E., Botz, Gregory H., Bucana, Corazon D., Koivunen, Erkki, Cahill, Dolores, Troncoso, Patricia, Baggerly, Keith A., Pentz, Rebecca D., Do, Kim-Anh, Logothetis, Christopher J., and Pasqualini, Renata

Abstract

The molecular diversity of receptors in human blood vessels remains largely unexplored. We developed a selection method in which peptides that home to specific vascular beds are identified after administration of a peptide library. Here we report the first in vivo screening of a peptide library in a patient. We surveyed 47,160 motifs that localized to different organs. This large-scale screening indicates that the tissue distribution of circulating peptides is nonrandom. High-throughput analysis of the motifs revealed similarities to ligands for differentially expressed cell-surface proteins, and a candidate ligand-receptor pair was validated. These data represent a step toward the construction of a molecular map of human vasculature and may have broad implications for the development of targeted therapies., Author(s): Wadih Arap (corresponding author) [1, 2]; Mikhail G. Kolonin [1, 11]; Martin Trepel [1, 11]; Johanna Lahdenranta [1]; Marina Cardo-Vila [1]; Ricardo J. Giordano [1]; Paul J. Mintz [1]; [...]

Published
2002
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results